160 related articles for article (PubMed ID: 16267275)
1. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism.
Robben JH; Sze M; Knoers NV; Deen PM
Mol Biol Cell; 2006 Jan; 17(1):379-86. PubMed ID: 16267275
[TBL] [Abstract][Full Text] [Related]
2. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
3. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
[TBL] [Abstract][Full Text] [Related]
6. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.
Bernier V; Lagacé M; Lonergan M; Arthus MF; Bichet DG; Bouvier M
Mol Endocrinol; 2004 Aug; 18(8):2074-84. PubMed ID: 15166253
[TBL] [Abstract][Full Text] [Related]
7. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation.
Tan CM; Nickols HH; Limbird LE
J Biol Chem; 2003 Sep; 278(37):35678-86. PubMed ID: 12824183
[TBL] [Abstract][Full Text] [Related]
8. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
Prosperi F; Suzumoto Y; Marzuillo P; Costanzo V; Jelen S; Iervolino A; Guarino S; La Manna A; Miraglia Del Giudice E; Perna AF; Zacchia M; Cordat E; Capasso G; Trepiccione F
Sci Rep; 2020 Oct; 10(1):16383. PubMed ID: 33009446
[TBL] [Abstract][Full Text] [Related]
9. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
10. Rescue of a nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutant by cell-penetrating peptides.
Oueslati M; Hermosilla R; Schönenberger E; Oorschot V; Beyermann M; Wiesner B; Schmidt A; Klumperman J; Rosenthal W; Schülein R
J Biol Chem; 2007 Jul; 282(28):20676-85. PubMed ID: 17491025
[TBL] [Abstract][Full Text] [Related]
11. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
[TBL] [Abstract][Full Text] [Related]
12. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G
J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667
[TBL] [Abstract][Full Text] [Related]
13. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
Robben JH; Deen PM
BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
[TBL] [Abstract][Full Text] [Related]
15. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
[TBL] [Abstract][Full Text] [Related]
16. Derlin-1 and p97/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors.
Schwieger I; Lautz K; Krause E; Rosenthal W; Wiesner B; Hermosilla R
Mol Pharmacol; 2008 Mar; 73(3):697-708. PubMed ID: 18048502
[TBL] [Abstract][Full Text] [Related]
17. Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1/ABCB4.
Gautherot J; Durand-Schneider AM; Delautier D; Delaunay JL; Rada A; Gabillet J; Housset C; Maurice M; Aït-Slimane T
J Biol Chem; 2012 Feb; 287(7):5070-8. PubMed ID: 22184139
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
Morello JP; Salahpour A; Laperrière A; Bernier V; Arthus MF; Lonergan M; Petäjä-Repo U; Angers S; Morin D; Bichet DG; Bouvier M
J Clin Invest; 2000 Apr; 105(7):887-95. PubMed ID: 10749568
[TBL] [Abstract][Full Text] [Related]
19. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors.
Wüller S; Wiesner B; Löffler A; Furkert J; Krause G; Hermosilla R; Schaefer M; Schülein R; Rosenthal W; Oksche A
J Biol Chem; 2004 Nov; 279(45):47254-63. PubMed ID: 15319430
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.
Mouillac B; Mendre C
Handb Exp Pharmacol; 2018; 245():63-83. PubMed ID: 28939971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
